Journal ArticleDOI
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Min Jun,Celine Foote,Jicheng Lv,Jicheng Lv,Bruce Neal,Anushka Patel,Stephen J. Nicholls,Diederick E. Grobbee,Alan Cass,John Chalmers,Vlado Perkovic +10 more
Reads0
Chats0
TLDR
Fibrates can reduce the risk of major cardiovascular events predominantly by prevention of coronary events, and might have a role in individuals at high risk of cardiovascular events and in those with combined dyslipidaemia.About:
This article is published in The Lancet.The article was published on 2010-05-29. It has received 821 citations till now. The article focuses on the topics: Sudden death & Cochrane Library.read more
Citations
More filters
Journal ArticleDOI
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association
Walter N. Kernan,Bruce Ovbiagele,Henry R. Black,Dawn M. Bravata,Marc I. Chimowitz,Michael D. Ezekowitz,Margaret C. Fang,Marc Fisher,Karen L. Furie,Donald V. Heck,S. Claiborne Johnston,Scott E. Kasner,Steven J. Kittner,Pamela H. Mitchell,Michael W. Rich,DeJuran Richardson,Lee H. Schwamm,John A. Wilson +17 more
TL;DR: In this paper, the authors provided evidence-based recommendations for the prevention of future stroke among survivors of ischemic stroke or transient ischemi-chemic attack, including the control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke.
Journal ArticleDOI
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆
Alberico L. Catapano,Zeljko Reiner,Guy De Backer,Ian D. Graham,Marja-Riitta Taskinen,Olov Wiklund,Stefan Agewall,Eduardo Alegria,M. John Chapman,Paul N. Durrington,Serap Erdine,Julian Halcox,Richard J. Hobbs,John Kjekshus,Pasquale Perrone Filardi,Gabriele Riccardi,Robert F. Storey,David R. Wood +17 more
TL;DR: These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians but also specialists from lipid clinics or metabolic units who are dealing with dyslipIDAemias that are more difficult to classify and treat.
Journal ArticleDOI
Progress and challenges in translating the biology of atherosclerosis
TL;DR: Understanding how to combine experimental and clinical science will provide further insight into atherosclerosis and could lead to new clinical applications.
Journal ArticleDOI
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino,Peter J. Grant,Victor Aboyans,Clifford J Bailey,Antonio Ceriello,Victoria Delgado,Massimo Federici,Gerasimos Filippatos,Diederick E. Grobbee,Tina Birgitte Hansen,Heikki V. Huikuri,I. Johansson,Peter Jüni,Maddalena Lettino,Nikolaus Marx,Linda Mellbin,Carl J. Östgren,Bianca Rocca,Marco Roffi,Naveed Sattar,Petar M. Seferović,Miguel Sousa-Uva,Paul Valensi,David C Wheeler +23 more
TL;DR: The second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidence-based management decisions.
Journal ArticleDOI
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano,Ian D. Graham,Guy De Backer,Olov Wiklund,M. John Chapman,Heinz Drexel,Arno W. Hoes,Catriona Jennings,Ulf Landmesser,Terje R. Pedersen,Željko Reiner,Gabriele Riccardi,Marja-Riitta Taskinen,Lale Tokgozoglu,W. M. Monique Verschuren,Charalambos Vlachopoulos,David R. Wood,José Luis Zamorano +17 more
TL;DR: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society and EAS and ABI : ankle-brachial index are formed.
References
More filters
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Mortality by cause for eight regions of the world: Global Burden of Disease Study
TL;DR: The Global Burden of Disease Study (GBD) used various data sources and made corrections for miscoding of important diseases (eg, ischaemic heart disease) to estimate worldwide and regional cause-of-death patterns in 1990, and the estimates by cause provide a foundation for a more informed debate on public-health priorities.
Journal ArticleDOI
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
Frick Mh,O. Elo,Haapa K,Olli P. Heinonen,P. Heinsalmi,P. Helo,Jussi K. Huttunen,Kaitaniemi P,Koskinen P,Manninen +9 more
TL;DR: Results are in accord with two previous trials with different pharmacologic agents and indicate that modification of lipoprotein levels with gemfibrozil reduces the incidence of coronary heart disease in men with dyslipidemia.
Journal ArticleDOI
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Hanna Bloomfield Rubins,Sander J. Robins,Dorothea Collins,Carol L. Fye,James W. Anderson,Marshall B. Elam,Fred H. Faas,Esteban Linares,Ernst J. Schaefer,Gordon Schectman,Timothy J Wilt,Janet Wittes +11 more
TL;DR: Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level, suggesting that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
Related Papers (5)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Anthony C Keech,R. J. Simes,Philip J. Barter,James D. Best,Russell S. Scott,Marja-Riitta Taskinen,Peta M. Forder,Avinesh Pillai,Tamara M. Davis,Paul Glasziou,Paul L. Drury,Y A Kesäniemi,David R. Sullivan,D Hunt,Peter G. Colman,Michael C d'Emden,Malcolm J. Whiting,Christian Ehnholm,Markku Laakso +18 more